Fractyl Health to Report Third Quarter 2026 Financial Results on November 12, 2026

Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026

Fractyl Health, a clinical-stage metabolic therapeutics company, announced it will report Q3 2026 financial results on November 12, 2026. The company is advancing its lead product Revita, an endoscopic procedural therapy for post-GLP-1 weight maintenance, toward FDA submission. Fractyl has strengthened its patent portfolio and released market research showing substantial patient interest in one-time procedural approaches, with approximately one million U.S. patients monthly discontinuing GLP-1 medications.

Fractyl Health Strengthens Revita Patent Portfolio

Fractyl Health reported the strengthening of its patent portfolio for its Revita DMR system as it progresses toward FDA submission.

Fractyl Health Announces Results of Market Research on GLP-1 Therapy Discontinuation

Fractyl Health released findings from a market survey indicating significant patient interest in a one-time procedural approach for weight maintenance following GLP-1 therapy.

Fractyl Health Announces Strategic Reprioritization and Workforce Reduction

Fractyl Health is sharpening its focus on its lead product candidate, Revita, while discontinuing its Rejuva gene therapy program and reducing its workforce by approximately 45%.

Fractyl Health Names Harith Rajagopalan President

Fractyl Health has appointed Harith Rajagopalan as president following the retirement of Jay Caplan.

Fractyl Health Announces Heightened Focus On Advancing Revita Toward Potential FDA Marketing Authorization And Commercialization In Post-GLP-1 Weight Maintenance